<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951947</url>
  </required_header>
  <id_info>
    <org_study_id>JS-201</org_study_id>
    <nct_id>NCT04951947</nct_id>
  </id_info>
  <brief_title>JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer</brief_title>
  <official_title>A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety&#xD;
      of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed&#xD;
      previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the&#xD;
      secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w,&#xD;
      lenvatinib 8mg po. Qd.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS201 combine with Lenvatinib</intervention_name>
    <description>JS201 300mg i.v Q2wLenvatinib 8mg po. Qd</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. The imaging diagnosis is the extensive stage of SCLC&#xD;
&#xD;
          -  2. The patient failed first-line EC+PD-L1 treatment&#xD;
&#xD;
          -  3 PS 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Diagnosed as non-small cell lung cancer&#xD;
&#xD;
          -  2. Women during pregnancy&#xD;
&#xD;
          -  3. Patients with symptomatic brain metastases&#xD;
&#xD;
          -  4. PSâ‰¥2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>7+861383123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Yang, MD</last_name>
    <phone>+8613055193557</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>yangnong0217@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>HunanPTH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

